---
title: "JonesTrading Reaffirms Their Buy Rating on Prime Medicine, Inc. (PRME)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285766225.md"
description: "JonesTrading analyst Boris Peaker has reaffirmed a Buy rating on Prime Medicine, Inc. (PRME) with a price target of $5.00. Peaker, a 5-star analyst, has an average return of 19.6% and a 45.36% success rate. Additionally, Chardan Capital's Geulah Livshits also issued a Buy rating for the company today, while H.C. Wainwright maintained a Hold rating on PRME."
datetime: "2026-05-08T19:16:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285766225.md)
  - [en](https://longbridge.com/en/news/285766225.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285766225.md)
generator: "portal-rs"
---

# JonesTrading Reaffirms Their Buy Rating on Prime Medicine, Inc. (PRME)

JonesTrading analyst Boris Peaker reiterated a Buy rating on Prime Medicine, Inc. today and set a price target of $5.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Peaker is a 5-star analyst with an average return of 19.6% and a 45.36% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Relay Therapeutics, Nuvation Bio, and OnKure Therapeutics.

In addition to JonesTrading, Prime Medicine, Inc. also received a Buy from Chardan Capital’s Geulah Livshits in a report issued today. However, on the same day, H.C. Wainwright reiterated a Hold rating on Prime Medicine, Inc. (NASDAQ: PRME).

### Related Stocks

- [PRME.US](https://longbridge.com/en/quote/PRME.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [RLAY.US](https://longbridge.com/en/quote/RLAY.US.md)
- [NUVB.US](https://longbridge.com/en/quote/NUVB.US.md)
- [OKUR.US](https://longbridge.com/en/quote/OKUR.US.md)
- [NUVB+.US](https://longbridge.com/en/quote/NUVB+.US.md)

## Related News & Research

- [Prime Medicine Maintained at Buy with Unchanged $6 Price Target on Emerging Program Clarity and 2027 Catalysts](https://longbridge.com/en/news/296139179.md)
- [Moderna surges on trial win for cancer shot; William Blair upgrades](https://longbridge.com/en/news/296370751.md)
- [SBIO: U.S. Programmatic and EMEA drove 49% of Q2 sales, with margins rising to 61% and profitability expected in H2 2026](https://longbridge.com/en/news/296517769.md)
- [Guotai Asset Management sees liquidity boost driving China biotech, innovation drug shares higher](https://longbridge.com/en/news/296448906.md)
- [LifeSci Capital Remains a Buy on Prime Medicine, Inc. (PRME)](https://longbridge.com/en/news/292381827.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**